Skip to main content
Max Kates, MD, Urology, Baltimore, MD

MaxKatesMD

Urology • Baltimore, MD

Physician

Join to view full profile

Dr. Kates is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kates' full profile

Already have an account?

  • Office

    Johns Hopkins
    600 N Wolfe St Tower 110
    Baltimore, MD 21287
    Phone+1 410-955-4020

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Urology, 2013 - 2018
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiClass of 2012

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2015 - 2026
  • American Board of Urology Urology

Publications & Presentations

PubMed

Journal Articles

  • Hospitalization and Readmission Costs After Radical Cystectomy in a Nationally Representative Sample: Does Urinary Reconstruction Matter?  
    Hiten D Patel, Meera R Chappidi, Trinity J Bivalacqua, Gregory A Joice, Phillip M Pierorazio, Max Kates, Nikolai A Sopko, BJU International

Authored Content

  • Primary Chemoablation of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm TrialAugust 2021

Press Mentions

  • Patients Talked; We Listened, Studied, and Came up with a Plan to Make It Better. Now We Want to Test It
    Patients Talked; We Listened, Studied, and Came up with a Plan to Make It Better. Now We Want to Test ItDecember 12th, 2023
  • NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer
    NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder CancerAugust 1st, 2022
  • AUA2021 Presentation Highlights Results from a Phase 1/2 Clinical Trial of Intramural/Intravesical NanoDoce® Suspension in High-Risk Nonmuscle Invasive Bladder Cancer
    AUA2021 Presentation Highlights Results from a Phase 1/2 Clinical Trial of Intramural/Intravesical NanoDoce® Suspension in High-Risk Nonmuscle Invasive Bladder CancerSeptember 21st, 2021
  • Join now to see all

Dr. Max Kates, Dr. Max Kates, MD, Dr. M Kates